Investor Relations

About AVROBIO

 

Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.

 

Sign up for email alerts

Stock Chart


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations

Our News Latest press releases

Nov 24, 2021

AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Safety data updates for Phase 1 and 2 Fabry disease clinical trials and Phase 1/2 Gaucher disease type 1 clinical trial show no adverse events or serious adverse events related to drug product CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- AVROBIO, Inc.

Read More

Nov 09, 2021

AVROBIO to Present at Two Upcoming Investor Conferences in November

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming

Read More

Nov 08, 2021

AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present safety data from its clinical trials in Fabry disease and Gaucher

Read More

See All

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.